CCL5 and rheumatoid arthritis: Furthermore, it has been shown that XFC can alleviate RA symptoms by inhibiting abnormal activation of the PI3K pathway and reducing IL-1β, IL-33, C-C motif chemokine ligand 5 (CCL5), and vascular endothelial growth factor (VEGF) expressions (35).